Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating income | -$29.7K | -$233K | -$2.34M | -$3.21M | -$4.69M | -$7.44M | -$10.3M | -$9.93M | -$10.1M | -$11.4M |
| Net income | -$29.7K | -$235K | -$2.34M | -$2.17M | -$4.66M | -$7.44M | -$10.1M | -$9.29M | -$9.83M | -$12.9M |
| EPS (diluted) | $0.00 | -$0.03 | -$1.84 | -$1.46 | -$1.26 | -$0.40 | — | -$3.14 | -$18.30 | -$12.52 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$18.5K | -$217K | -$1.61M | -$2.79M | -$4.35M | -$6.14M | -$8.01M | -$8.21M | -$8.35M | -$8.52M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $3.59K | $573K | $337K | $4.42M | $2.14M | $6.63M | $6.89M | $2.81M | $2.34M | $600K |
| Total assets | $3.59K | $574K | $397K | $6.48M | $4.38M | $12.6M | $20.4M | $13.0M | $4.70M | $2.80M |
| Total liabilities | $17.4K | — | — | — | $501K | $593K | $1.02M | $1.29M | $1.84M | $4.07M |
| Shareholders' equity | -$13.8K | $545K | -$135K | $5.46M | $3.88M | $27.2M | $19.4M | $11.8M | $2.86M | -$1.27M |
| Retained earnings | -$60.2K | -$295K | -$2.64M | -$4.81M | -$9.47M | -$16.9M | -$31.0M | -$40.3M | -$50.1M | -$63.0M |
| Shares (wtd avg diluted) | 7.64M | 1.93M | 1.28M | 2.17M | 4.99M | 1.64M | 2.86M | 2.96M | 537K | 1.03M |
Every figure is extracted from ARTELO BIOSCIENCES, INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.